Evidence map›Paper›PMID 40402349›Full record

ArticleDiscover oncology2025

Comprehensive analysis Neddylation-related genes identified UBB as a prognostic biomarker for clear cell renal cell carcinoma.

Shengren Cen, Yingpeng Li, Xinhao Xiong, Zihong Ma, Yongsheng Wang, Xingcheng Gao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shengren Cen *Guangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Institute of Urology, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Yingpeng Li *Guangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Institute of Urology, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Xinhao Xiong *Guangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Institute of Urology, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Zihong MaGuangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Institute of Urology, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Yongsheng WangGuangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Institute of Urology, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China.
Xingcheng GaoGuangdong Provincial Key Laboratory of Urological Diseases, Guangzhou Institute of Urology, Department of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510230, Guangdong, China. xchgao@gzhmu.edu.cn.

Funding

The Science and Technology Plan Project of Guangzhou No.202201020562
6 · The paper itself

Abstract

Neddylation, as a type of post-translational modification, plays a key role in cancer development. However, the biological characteristics and clinical prognosis value of Neddylation-related genes (NRGs) signatures in clear cell renal cell carcinoma (ccRCC) remain undetermined. Here, we identified two subtypes of NRGs in ccRCC based on TCGA data and constructed a NRGs risk signature (NRGS). Survival analysis, ROC curves, and nomograms showed that NRGS was an important predictor of prognosis in patients with clear cell renal cell carcinoma. We further revealed important correlations between NRGS and clinicopathological features, gene mutations, drug sensitivity, and immune cell infiltration. High NRGS indicates a poorer prognosis for kidney cancer, but higher remission rates with immunotherapy. Drug sensitivity also varies across risk groups. UBB was identified as a hub gene for NRGS and was downregulated in ccRCC, which is associated with poor prognosis. In conclusion, this study provides strategies for predicting prognosis and individualizing treatment for ccRCC.

Indexed as

Clear cell renal cell carcinomaDrug sensitivityImmune environmentNeddylationPrognosisUBB

Identifiers

PMID40402349
PMCPMC12098231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.